A scoping review found very limited evidence for cannabinoids in OCD treatment, consisting mainly of surveys and case reports with no well-controlled trials, while psilocybin showed a stronger preliminary signal for treatment-resistant OCD.
Psychiatrists treating OCD, patients with treatment-resistant OCD exploring options, and researchers prioritizing novel therapeutic targets.
No controlled evidence for cannabinoids in OCD; psilocybin more promising
What the researchers found
The evidence for cannabinoids in OCD consists of cross-sectional surveys, case reports, and very few controlled trials, and appears to indicate a lack of efficacy for both synthetic and natural cannabinoids. In contrast, psilocybin shows a stronger signal for treatment-resistant OCD. 40-60% of OCD patients remain unresponsive to standard pharmacotherapy.
Why it matters
With 40-60% of OCD patients treatment-resistant, interest in novel agents is high. This review provides a reality check: despite enthusiasm, cannabinoid evidence for OCD is essentially absent, redirecting attention toward psychedelics where the signal appears stronger.
The numbers in context
40-60% of OCD patients are treatment-resistant. Cannabinoid evidence: cross-sectional surveys and case reports, no rigorous RCTs. No support for synthetic or natural cannabinoids in OCD. Psilocybin shows stronger preliminary signal.
How the study worked
Comprehensive scoping review of OCD literature including published and grey literature, examining evidence for cannabinoids, psilocybin, LSD, DMT, and MDMA in OCD treatment.
What this study cannot tell us
Scoping review, not a systematic review with meta-analysis. The absence of evidence for cannabinoids does not prove absence of effect. Very few studies exist for any of the agents reviewed. Comparison across substance classes is indirect.
How to read the evidence
Moderate: comprehensive scoping review covering multiple substance classes, limited by the sparse evidence base for all agents reviewed.
When this study was published
Published 2026.
The bigger picture
This review highlights an important distinction: cannabis users with OCD may self-report symptom relief in surveys, but controlled research does not support cannabinoids as an effective OCD treatment. The disconnect between self-reported benefit and clinical evidence is a recurring theme in cannabinoid research.
Questions still open
- Why do some OCD patients report subjective improvement with cannabis despite negative controlled evidence? Could specific cannabinoid formulations or doses be effective where general cannabis is not? Should research resources focus on psilocybin over cannabinoids for OCD?
Common questions
Can cannabis help with OCD?
What alternative treatments exist for treatment-resistant OCD?
Read the original research
New treatments for OCD? Evidence for cannabinoids and psychedelics.
Journal of psychiatric research, 193, 172-178
Citation
Van Ameringen, Michael; Patel, Vidhi; Patterson, Beth; Hopkinson, Paige; Rahat, Maryam. (2026). New treatments for OCD? Evidence for cannabinoids and psychedelics.. Journal of psychiatric research, 193, 172-178. https://doi.org/10.1016/j.jpsychires.2025.11.021
Explore the wider topic
- LGBTQ+ and Cannabis: Higher Use Rates and Recovery
- Cannabis-Induced Psychosis: What It Is, Who's at Risk, and What to Do
- BetterHelp, Cerebral, and Online Therapy: Honest Review
- Quitting Weed with ADHD: Why It Is Harder and What Actually Helps
- Quitting Weed with Depression: What You Need to Know
- Quitting Weed with PTSD: A Practical Guide
- Self-Medicating with Weed: Why It Works Until It Doesn't
- Weed and OCD: Self-Medicating Intrusive Thoughts
- Weed and PTSD: What the Research Actually Shows
- Weed and Childhood Trauma: ACEs, Self-Medication, and the Path to Real Healing
- Weed and Suicidal Thoughts: What You Need to Know